Skip to content

Postoperative Pain Management After Minimally Invasive Aortic Valve Surgery

Efficacy of Ropivacaine Wound Infiltration for Postoperative Pain Management After Minimally Invasive Aortic Valve Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03079830
Acronym
PPMAMIAVS
Enrollment
76
Registered
2017-03-15
Start date
2016-10-31
Completion date
2018-01-11
Last updated
2019-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Surgery, Postoperative; Pain

Keywords

aortic valve surgery, postoperative pain

Brief summary

The study evaluates the efficacy of local anesthestic application through the catheter in the surgical wound for the postoperative pain relief after minimally invasive aortic valve surgery. The patients will be enrolled in two different groups according to the protocol of the local anesthetic and saline administration: 1. group: continous infusion of the local anesthetic plus bolus on demand 2. group: continous infusion of saline plus bolus on demand For all patients metamizol every 12 hours plus bolous of piritramid on demand.

Detailed description

Patients undergoing minimally invasive aortic valve replacment surgery will be enroled in the study, after giving a signed informed consent. The study evaluates the efficacy of local anesthestic application through the catheter in the surgical wound for the postoperative pain relief after minimally invasive aortic valve surgery. Patients will then be randomised in two groups according to the protocol: 1. group: continous infusion of the local anesthetic plus bolus on demand 2. group: continous infusion of saline plus bolus on demand All patients will receive Metamizol every 12 hours plus bolus of piritramid on demand. Analgesia effectivness will be checked hourly according to the visual analogue scale (VAS). According to protocol, bolus will be given every time the score of VAS scale is \>3. The catheter will be removed 48 hours after the protocols' start.

Interventions

Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.

DRUGSaline

Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.

Sponsors

University Medical Centre Ljubljana
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients after minimally invasive aortic valve surgery * Patients agreement with the study

Exclusion criteria

* Age under 18 years * Allergy to local anesthetic

Design outcomes

Primary

MeasureTime frameDescription
Comparison of cumulative postoperative dose of Piritramid between the two different protocols, using VAS scale to determine level of analgesia.48 hours after admission to the intensive care unit (ICU)Comparison of cumulative postoperative dose of Piritramid between the two protocols

Secondary

MeasureTime frameDescription
Complications related to the catheter in the surgical woundUp to 30 daysComplications related to the catheter in the surgical wound
Visual analogue scale (VAS), frequency of scores higher than 348 hours after admission to the ICUVisual analogue scale (VAS), frequency of scores higher than 3
Patients satisfaction with pain relief measured by Likert-type Patient satisfaction scale72 hours after surgeryPatients satisfaction regarding pain relief, in the following order 1.very satisfied 2.satisfied 3.neither satisfied nor dissatisfied 4.dissatisfied 5.completely dissatisfied
Rate of complications related to the local anesthetic72 hours after surgeryNeurotoxicity and cardiotoxicity related to the local anesthetic
Hospital lenght of stayUp to 30 daysHospital lenght of stay

Countries

Slovenia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026